# Gilead Sciences

> American company

**Wikidata**: [Q663596](https://www.wikidata.org/wiki/Q663596)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/Gilead_Sciences)  
**Source**: https://4ort.xyz/entity/gilead-sciences

## Summary
Gilead Sciences is a publicly traded American biotechnology company founded in 1987, known for developing treatments for HIV, hepatitis, and cancer immunotherapies. It operates as a major player in the pharmaceutical industry, with significant revenue and assets, and owns Kite Pharma, a cancer immunotherapy-focused biomedical engineering firm. Headquartered in the United States, Gilead has evolved into a global leader in antiviral and oncology drug development.

## Key Facts
- Founded in June 1987.
- Public company listed on the stock exchange.
- Operates Kite Pharma, a biomedical engineering company based in Santa Monica, California, founded in 2009.
- Industry: Biotechnology and pharmaceuticals.
- Headquarters: United States.
- Notable for its role in developing life-saving antiviral and cancer immunotherapy drugs.
- Employs between 10,000 and 11,800 people.
- Revenue ranges from $4.2 billion to over $32.6 billion across multiple years.
- Net profit ranges from $123 million to $18.1 billion.
- Total assets range from $2.6 billion to $63.4 billion.
- Website: [https://www.gilead.com/](https://www.gilead.com/)

## FAQs
### When was Gilead Sciences founded?
Gilead Sciences was founded in June 1987.

### What does Gilead Sciences do?
Gilead Sciences is a biotechnology company focused on developing antiviral and cancer treatments, including ownership of Kite Pharma, a company specializing in cancer immunotherapies.

### How many people work at Gilead Sciences?
Gilead employs between 10,000 and 11,800 people.

### What is Kite Pharma's relationship to Gilead Sciences?
Kite Pharma is a subsidiary of Gilead Sciences, focused on developing cancer immunotherapies, and is based in Santa Monica, California.

### What are Gilead Sciences' financials?
Gilead's revenue ranges from $4.2 billion to over $32.6 billion, with net profits ranging from $123 million to $18.1 billion. Total assets range from $2.6 billion to $63.3 billion.

### Where is Gilead Sciences headquartered?
Gilead Sciences is headquartered in the United States.

### What industry is Gilead Sciences in?
Gilead Sciences operates in the biotechnology and pharmaceutical industry.

## Why It Matters
Gilead Sciences plays a critical role in global healthcare by developing breakthrough treatments for HIV, hepatitis, and cancer. Its innovations have saved millions of lives, particularly through antiretroviral therapies and immunotherapies. The company's acquisition of Kite Pharma expanded its reach into oncology, reinforcing its position as a leader in biotechnology. Its work has influenced global treatment protocols and has been instrumental in addressing viral diseases and cancer, making it a cornerstone in modern pharmaceutical innovation.

## Notable For
- Pioneering antiviral treatments that have become global standards for HIV and hepatitis.
- Owning Kite Pharma, a leader in CAR-T cell therapy for cancer.
- Consistently high revenue and net profit, indicating strong market performance.
- A diverse portfolio spanning multiple therapeutic areas including infectious diseases and oncology.
- Long-standing presence in the biotech industry since 1987.

## Body

### History
Gilead Sciences was founded in June 1987 and has since grown into a global biotechnology leader. The company’s inception marked the beginning of a new era in antiviral drug development. Over the years, Gilead has acquired companies and assets to expand its reach, including Kite Pharma in 2009, which focuses on cancer immunotherapies. This acquisition allowed Gilead to enter the oncology space with a strong foothold, leveraging Kite Pharma’s CAR-T cell therapy innovations.

### Operations and Structure
Gilead Sciences is a public company with a diversified portfolio in biotechnology. It operates across multiple therapeutic areas, including HIV, hepatitis, and cancer. The company’s structure includes a wholly owned subsidiary, Kite Pharma, which specializes in biomedical engineering and cancer immunotherapy development. Gilead’s operational model includes a strong focus on research and development, with revenues and assets that have varied significantly over time, reaching up to $63.3 billion in total assets.

### Subsidiary: Kite Pharma
Kite Pharma, acquired by Gilead, is a biomedical engineering company based in Santa Monica, California. It was incorporated in 2009 and focuses on cancer immunotherapies. Kite Pharma’s innovations in CAR-T cell therapy have positioned it as a leader in oncology treatments. It operates under Gilead Sciences and contributes to the company's oncology portfolio.

### Financials
Gilead Sciences has demonstrated strong financial performance over time. Its revenue has ranged from $4.2 billion to $32.6 billion, with net profits ranging from $123 million to $18.1 billion. The company’s total assets have grown to $63.3 billion, indicating its strong market presence. Gilead employs between 10,000 and 11,800 individuals and continues to invest heavily in research and development.

### Industry and Impact
Gilead Sciences operates in the biotechnology and pharmaceutical industry, focusing on life-saving treatments. Its work in antiviral and cancer therapies has had a global impact, particularly in HIV and hepatitis treatment. The company’s drugs are used worldwide, and its innovations have influenced treatment standards. Gilead’s acquisition of Kite Pharma has expanded its influence in oncology, making it a key player in cancer immunotherapy.

### Leadership and Structure
Gilead Sciences is a public company with a diversified portfolio and global influence. It operates in the United States and has consistently delivered high-value treatments. The company’s structure includes a strong focus on research and development, with a significant number of employees and assets. Gilead’s leadership in the industry is evident through its strong financials and global impact.

### Research and Development
Gilead Sciences is known for its strong focus on research and development. The company’s work in antiviral and cancer therapies has led to breakthrough treatments. Its acquisition of Kite Pharma has expanded its reach into oncology, making it a leader in cancer immunotherapy. Gilead’s research has led to life-saving treatments and has positioned it as a leader in the biotechnology industry.

## References

1. [Source](https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm)
2. [Source](https://www.lobbyfacts.eu/datacard/gilead-sciences?rid=258845020786-10)
3. [Source](http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDAxMzExfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636573297626432618)
4. [Source](https://www.bloomberg.com/research/stocks/people/person.asp?personId=39345031&privcapId=29002)
5. GRID Release 2017-01-10
6. [Source](https://www.ishares.com/us/products/239723/ishares-sp-100-etf)
7. [Source](https://www.fsa-pharma.de/de/der-fsa/mitgliedschaft/unsere-mitglieder/)
8. Freebase Data Dumps. 2013
9. [Source](http://investors.gilead.com/static-files/1a607ba4-ee05-4dc5-9eeb-9509c6b8a3e4)
10. Google Knowledge Graph
11. [Source](http://km.aifb.kit.edu/services/crunchbase/)
12. [Form 10-K. 2010](https://www.sec.gov/Archives/edgar/data/0000882095/000119312510044753/d10k.htm)
13. [Form 10-K. 2011](https://www.sec.gov/Archives/edgar/data/0000882095/000119312511050041/d10k.htm)
14. [Form 10-K. 2012](https://www.sec.gov/Archives/edgar/data/0000882095/000119312512075335/d260199d10k.htm)
15. [Form 10-K. 2013](https://www.sec.gov/Archives/edgar/data/0000882095/000088209513000015/a2012form10-k.htm)
16. [Form 10-K. 2021](https://www.sec.gov/Archives/edgar/data/0000882095/000088209521000008/gild-20201231.htm)
17. [Form 10-K. 2022](https://www.sec.gov/Archives/edgar/data/0000882095/000088209522000007/gild-20211231.htm)
18. [Form 10-K. 2023](https://www.sec.gov/Archives/edgar/data/0000882095/000088209523000007/gild-20221231.htm)
19. GRID Release 2015-12-14
20. GRID Release 2016-12-06
21. [2020](https://www.gleif.org/content/4-lei-data/8-lei-mapping/1-download-bic-to-lei-relationship-files/bic_lei_gleif_v1_monthly_full_20200327.csv)
22. [Form 10-K. 2014](https://www.sec.gov/Archives/edgar/data/0000882095/000088209514000013/a2013form10-k.htm)
23. [Form 10-K. 2015](https://www.sec.gov/Archives/edgar/data/0000882095/000088209515000008/a2014form10-k.htm)
24. Aligned ISNI and Ringgold identifiers for institutions
25. [Source](https://golden.com/wiki/Gilead_Sciences-4NVMX8)
26. YouTube API
27. Wikirate